Tilia Fiduciary Partners Inc. Grows Position in Thermo Fisher Scientific Inc. $TMO

Tilia Fiduciary Partners Inc. grew its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 10.1% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 4,534 shares of the medical research company’s stock after purchasing an additional 415 shares during the period. Tilia Fiduciary Partners Inc.’s holdings in Thermo Fisher Scientific were worth $1,838,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. CBIZ Investment Advisory Services LLC grew its stake in Thermo Fisher Scientific by 137.5% during the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock worth $28,000 after buying an additional 33 shares during the period. Anderson Financial Strategies LLC purchased a new stake in Thermo Fisher Scientific during the first quarter worth approximately $30,000. Keystone Global Partners LLC purchased a new position in shares of Thermo Fisher Scientific in the first quarter valued at $31,000. IMA Advisory Services Inc. purchased a new position in shares of Thermo Fisher Scientific in the first quarter valued at $35,000. Finally, Smallwood Wealth Investment Management LLC purchased a new position in shares of Thermo Fisher Scientific in the first quarter valued at $37,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares in the company, valued at $10,735,712.66. This represents a 1.76% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the transaction, the chief accounting officer owned 2,319 shares of the company’s stock, valued at $1,142,408.97. This represents a 14.24% decrease in their position. The disclosure for this sale can be found here. Insiders sold 30,066 shares of company stock worth $14,182,963 in the last 90 days. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Up 3.6%

Thermo Fisher Scientific stock opened at $543.88 on Friday. The company has a 50-day simple moving average of $482.58 and a 200-day simple moving average of $447.76. The firm has a market capitalization of $205.37 billion, a P/E ratio of 31.46, a P/E/G ratio of 2.85 and a beta of 0.77. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping the consensus estimate of $5.22 by $0.14. The business had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company’s quarterly revenue was up 2.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is currently 9.95%.

Analyst Upgrades and Downgrades

TMO has been the subject of several analyst reports. Evercore ISI decreased their target price on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an “outperform” rating for the company in a research note on Tuesday, July 8th. Scotiabank upgraded shares of Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 target price for the company in a research note on Friday, July 11th. Royal Bank Of Canada set a $561.00 target price on shares of Thermo Fisher Scientific and gave the company an “outperform” rating in a research note on Tuesday, September 2nd. Barclays upped their price target on shares of Thermo Fisher Scientific from $550.00 to $585.00 and gave the company an “overweight” rating in a report on Thursday. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Thermo Fisher Scientific in a report on Saturday, September 27th. Fifteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $585.37.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.